Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iparomlimab + tuvorralimab
- Development stage
- Phase 2
- Lead developer
- Qilu Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Iparomlimab + tuvorralimab (QL1706) is a novel bifunctional biologic combination developed by Qilu Pharmaceutical using its proprietary MabPair technology. It consists of two engineered monoclonal antibodies—iparomlimab, an anti-PD-1 IgG4 antibody, and tuvorralimab, an anti-CTLA-4 IgG1 antibody—produced by a single cell line and combined in a fixed 2:1 ratio. This dual-checkpoint inhibitor is designed to simultaneously block the PD-1 and CTLA-4 pathways, potentially offering superior efficacy and a more manageable safety profile compared to traditional combinations of separate antibodies. QL1706 is currently being evaluated in Phase 2 and Phase 3 clinical trials for various malignancies, including cervical cancer, non-small cell lung cancer, esophageal squamous cell carcinoma, and hepatocellular carcinoma.
- Brand names
- 齐倍安
- Other names
- iparomlimab and tuvorralimabtuvonralimab
02
Targets
FcγR/C1q (Fc gamma receptors and complement component C1q)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on iparomlimab + tuvorralimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iparomlimab + tuvorralimab.